Laryngeal cancer
Drug research and approvals for laryngeal cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 81 studies of laryngeal cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 81
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Compressive Dressing and Pharyngocutaneous Fistula After Primary Total LaryngectomyNCT07949526 · Not reported · IRCCS San Raffaele · starts May 5, 2025
- TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell CarcinomaNCT07898124 · Phase 1 · Metaclipse Therapeutics Corporation · starts Oct 1, 2026
- Intraoperative Methadone for the Management of Postoperative Pain in Patients With Head and Neck CancersNCT07857655 · Phase 4 · OHSU Knight Cancer Institute · starts Sep 22, 2026
- A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing…NCT07807163 · Phase 2 · Bicara Therapeutics · starts Sep 1, 2026
- Scheduled IV Fluids in the Supportive Management of Patients Undergoing Chemo-radiotherapy for Head and Neck CancerNCT07784855 · Not applicable · West Virginia University · starts Nov 1, 2026
- Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality…NCT07741643 · Phase 1 · Vanderbilt-Ingram Cancer Center · starts Sep 15, 2026
- Thermotherapy for Head and Neck Cancer PatientsNCT07690618 · Phase 1 · Erasmus Medical Center · starts Sep 1, 2026
- Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and…NCT07667400 · Phase 1 / Phase 2 · National Cancer Institute (NCI) · starts Nov 25, 2026
- A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous LesionsNCT07532538 · Not reported · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · starts Apr 30, 2026
Phase 3 7
- CisplatinDNA inhibitor
- DocetaxelTubulin inhibitor
- FluorouracilThymidylate synthase inhibitor
- CarboplatinDNA inhibitor
- HydroxyureaRibonucleoside-diphosphate reductase RR1 inhibitor
- CefazolinBacterial penicillin-binding protein inhibitor
- 5-fluoronicotinic acid
Phase 2 3
- CetuximabEpidermal growth factor receptor erbB1 inhibitor
- IsosorbideOsmotic agent
- OxygenEssential for cellular homeostasis
How its trials ended
216 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 48 whose ending is known, 19% met their primary endpoint, 2% missed it and 79% stopped early.
- Completed, result not reported9142%
- Ongoing5726%
- Status unknown209%
- Stopped: other or unclear157%
- Stopped: enrollment or feasibility126%
- Met its primary endpoint94%
- Stopped: sponsor or business decision52%
- Stopped: funding42%
- Missed its primary endpoint1<1%
- Stopped: lack of efficacy1<1%
- Stopped: safety1<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA